BRPI0710682B8 - combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol - Google Patents

combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol

Info

Publication number
BRPI0710682B8
BRPI0710682B8 BRPI0710682A BRPI0710682A BRPI0710682B8 BR PI0710682 B8 BRPI0710682 B8 BR PI0710682B8 BR PI0710682 A BRPI0710682 A BR PI0710682A BR PI0710682 A BRPI0710682 A BR PI0710682A BR PI0710682 B8 BRPI0710682 B8 BR PI0710682B8
Authority
BR
Brazil
Prior art keywords
paracetamol
dimethylamino
phenol
propyl
ethyl
Prior art date
Application number
BRPI0710682A
Other languages
English (en)
Inventor
Schiene Klaus
Bloms-Funke Petra
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37025148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0710682(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BRPI0710682A2 publication Critical patent/BRPI0710682A2/pt
Publication of BRPI0710682B1 publication Critical patent/BRPI0710682B1/pt
Publication of BRPI0710682B8 publication Critical patent/BRPI0710682B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

combinação farmacéutica consistente de 3-(3-dimetilamino-1- etil-2-metil-propil)-fenol e paracetamol. a presente invenção relaciona-se a uma combinação que contém como componentes, (a) o composto 3-(3-dimetilamino-1-etií-2-metil-propil)-fenol, e (b) paracetamol ou um derivado do mesmo, uma formulação farmacêutica e uma forma de dosagem que consiste da combinação mencionada assim como um método de tratar a dor, ex. dor crônica ou aguda, caracterizada pelos componentes (a) e (b) serem administrados simultaneamente ou seqüencialmente a um mamífero, onde o componente (a) pode ser administrado antes ou após o componente (b) e onde os componentes (a) ou (b) são administrados ao mamífero já seja por meio da mesma via ou de uma via diferente de administração.
BRPI0710682A 2006-04-28 2007-04-25 combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol BRPI0710682B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06008851.5 2006-04-28
EP06008851 2006-04-28
PCT/EP2007/003632 WO2007128413A1 (en) 2006-04-28 2007-04-25 Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol

Publications (3)

Publication Number Publication Date
BRPI0710682A2 BRPI0710682A2 (pt) 2011-08-23
BRPI0710682B1 BRPI0710682B1 (pt) 2020-09-24
BRPI0710682B8 true BRPI0710682B8 (pt) 2021-05-25

Family

ID=37025148

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710682A BRPI0710682B8 (pt) 2006-04-28 2007-04-25 combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol

Country Status (25)

Country Link
EP (1) EP2012764B1 (pt)
JP (2) JP5496653B2 (pt)
KR (1) KR101396166B1 (pt)
CN (1) CN101431990B (pt)
AT (1) ATE494889T1 (pt)
AU (1) AU2007247481B2 (pt)
BR (1) BRPI0710682B8 (pt)
CA (1) CA2650423C (pt)
CY (1) CY1111369T1 (pt)
DE (1) DE602007011913D1 (pt)
DK (1) DK2012764T3 (pt)
EC (2) ECSP088793A (pt)
ES (1) ES2356093T3 (pt)
HK (1) HK1127289A1 (pt)
HR (1) HRP20110076T1 (pt)
IL (1) IL194883A (pt)
MX (1) MX2008013779A (pt)
NO (2) NO341602B1 (pt)
NZ (1) NZ571442A (pt)
PL (1) PL2012764T3 (pt)
PT (1) PT2012764E (pt)
RU (1) RU2442576C2 (pt)
SI (1) SI2012764T1 (pt)
WO (1) WO2007128413A1 (pt)
ZA (1) ZA200810124B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP3170494A3 (en) * 2007-11-23 2017-09-06 Grünenthal GmbH Tapentadol compositions
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
EP3287123B1 (en) 2011-03-04 2020-04-22 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
EP3025710A1 (en) 2011-03-04 2016-06-01 Grünenthal GmbH Parenteral administration of tapentadol
US9446008B2 (en) 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
WO2016156147A1 (en) 2015-03-27 2016-10-06 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
PE20190908A1 (es) 2016-09-23 2019-06-26 Gruenenthal Chemie Formulacion estable para la administracion parenteral de tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
HUE033042T2 (en) * 2002-11-22 2017-11-28 Gruenenthal Gmbh Combination of selected analgesics with COX II inhibitors

Also Published As

Publication number Publication date
ECSP17000643A (es) 2018-06-30
AU2007247481A1 (en) 2007-11-15
CY1111369T1 (el) 2015-08-05
EP2012764A1 (en) 2009-01-14
BRPI0710682A2 (pt) 2011-08-23
ES2356093T3 (es) 2011-04-04
RU2442576C2 (ru) 2012-02-20
EP2012764B1 (en) 2011-01-12
CA2650423A1 (en) 2007-11-15
JP2013213045A (ja) 2013-10-17
PT2012764E (pt) 2011-02-02
BRPI0710682B1 (pt) 2020-09-24
CA2650423C (en) 2014-08-12
KR20090006219A (ko) 2009-01-14
IL194883A (en) 2012-10-31
DK2012764T3 (da) 2011-02-28
NO341602B1 (no) 2017-12-11
HK1127289A1 (en) 2009-09-25
NO343505B1 (no) 2019-03-25
NO20084542L (no) 2008-10-28
JP5496653B2 (ja) 2014-05-21
SI2012764T1 (sl) 2011-03-31
JP2009535313A (ja) 2009-10-01
CN101431990B (zh) 2011-08-03
DE602007011913D1 (de) 2011-02-24
MX2008013779A (es) 2008-11-14
WO2007128413A1 (en) 2007-11-15
PL2012764T3 (pl) 2011-04-29
HRP20110076T1 (hr) 2011-02-28
ZA200810124B (en) 2009-08-26
NZ571442A (en) 2011-09-30
NO20171831A1 (no) 2008-10-28
RU2008146816A (ru) 2010-06-10
ATE494889T1 (de) 2011-01-15
IL194883A0 (en) 2009-08-03
KR101396166B1 (ko) 2014-05-27
AU2007247481B2 (en) 2013-02-14
CN101431990A (zh) 2009-05-13
ECSP088793A (es) 2008-11-27

Similar Documents

Publication Publication Date Title
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
WO2010025931A3 (en) Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
BRPI0622054B8 (pt) composto e composição farmacêutica
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2007143607A3 (en) Method of treating atrophic vaginitis
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
CL2007003284A1 (es) Composicion farmaceutica que comprende una asociacion de i) ciclobenzaprina, ii) aceclofenaco y opcionalmente iii) excipientes; y su uso para el tratamiento de enfermedades musculares dolorosas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF